4300 Hacienda Drive
Roche Molecular Solutions, one of the global business areas within Roche Diagnostics, brings together the diagnostic power of molecular, tissue and sequencing technologies.
With the goal of revolutionizing diagnostic decisions through integrated solutions, Roche Molecular Solutions brings together the latest technologies withinmolecular diagnostics (polymerase chain reaction or PCR-based testing), tissue diagnostics (tissue biopsy testing) and sequencing solutions (next-generation DNA and RNA sequence-based testing) to advance the standard of care for everyone.
Roche is the world leader in molecular and tissue diagnostics, and one of the leaders in clinical sequencing. As the innovation engine for Roche Diagnostics,Roche Molecular Solutions is translating cutting-edge science and innovation into clinical practice.
Visit our Career Blogs to see what our employees have to say about their life at Roche!
99 articles with Roche
Despite the advances in personalized medicine, a new survey of 1,001 Americans shows that the majority are not familiar with the concept.
Curis Expands Senior Management Expertise with Appointment of Robert Martell, M.D., Ph.D., as Head of Research and Development
Curis, Inc. today announced that Robert Martell, M.D., Ph.D., has been appointed Head of Research and Development.
coreHEM Publishes Core Outcome Set for Hemophilia Clinical Trials; Prepares to Launch Next Phase of Work
The coreHEM initiative has announced the publication of a core outcome set for clinical trials of gene therapy in hemophilia.
Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.
Pierre Fabre announced today the extension of a collaboration agreement with Roche on companion diagnostic development for W0101.
5/18/2018In order to drive the manufacture of affordable generic drugs, the U.S. Food and Drug Administration is naming names of companies that have attempted to block competition.
Johnson & Johnson’s Janssen division has decided to end its trials of atabacestat, a BACE inhibitor, for Alzheimer’s disease.
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), today reported financial results for the first quarter and provided a review of recent accomplishments and anticipated upcoming milestones.
New claim allows for streamlined screening of pooled blood or plasma donations
Exelixis Provides Update on IMblaze370 Phase 3 Pivotal Trial of Atezolizumab and Cobimetinib in Patients With Heavily Pretreated Locally Advanced or Metastatic Colorectal Cancer
The study did not meet its primary endpoint of improving overall survival versus regorafenib. Results will be submitted for presentation at an upcoming medical meeting.
The U.S. Food and Drug Administration (FDA) granted Genentech’s Tecentriq triple combination with Avastain (bevacizumab), paclitaxel and carboplatin (chemotherapy) Priority Review for first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC).
Just about every week has plenty of exciting news in the biopharmaceutical industry, and this week was no different. Here’s a brief look back at some of our top stories.
According to Biosimilarpipeline, more than 660 companies worldwide have about 700 biosimilars in development.
While the biopharma industry awaits news of an acquisition of Shire by Takeda Pharmaceuticals, it’s a good time to take a look back at the bigger deals so far this year.
Bristol-Myers Squibb announced that it has expanded its relationship with Flatiron Health, extending a three-year collaboration agreement.
The U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) to Sandoz, a division of Novartis, for its Biologics Licensing Application (BLA) for its biosimilar to Roche/Genentech’s Rituxan.
NeoImmuneTech Announces a Clinical Trial Collaboration with a Global Leading Pharmaceutical Company to Evaluate HyLeukin-7 in Combination with a PD-L1 Checkpoint Inhibitor in Advanced High-Risk Skin Cancers
NeoImmuneTech have entered into an agreement with Roche to enable studies of a combination treatment in three advanced high-risk skin cancer types.
4DMT and ROCHE Expand Ophthalmology Partnership to Develop and Commercialize Multiple AAV Gene Therapy Products
4D Molecular Therapeutics today announced the expansion of its 2016 research agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. into a broad long-term partnership to develop and commercialize multiple ophthalmology products.
Sanofi announced that Elias Zerhouni, head of Global Research and Development, is retiring on June 30. The company has appointed John Reed to replace him as of July 1.
The FDA Giveth and Taketh Away: Grants Pfizer's MenB Breakthrough Therapy Designation and Turns D...
4/23/2018The FDA granted Pfizer’s Trumenba, a vaccine for meningococcal B disease in children ages one to nine years, Breakthrough Therapy Designation and declined to approve its biosimilar of Roche's Herceptin for breast cancer.